223 related articles for article (PubMed ID: 35760800)
41. A new osteoclastogenesis pathway induced by cancer cells targeting osteoclast precursor cells.
Wada A; Tsuchiya M; Ozaki-Honda Y; Kayamori K; Sakamoto K; Yamaguchi A; Ikeda T
Biochem Biophys Res Commun; 2019 Jan; 509(1):108-113. PubMed ID: 30578079
[TBL] [Abstract][Full Text] [Related]
42. Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner.
Pellegrini GG; Morales CC; Wallace TC; Plotkin LI; Bellido T
Nutrients; 2016 Jul; 8(7):. PubMed ID: 27409635
[TBL] [Abstract][Full Text] [Related]
43. Myeloma bone disease.
Sezer O
Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
[TBL] [Abstract][Full Text] [Related]
44. Breast cancer metastasis to the bone: mechanisms of bone loss.
Chen YC; Sosnoski DM; Mastro AM
Breast Cancer Res; 2010; 12(6):215. PubMed ID: 21176175
[TBL] [Abstract][Full Text] [Related]
45. MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.
Zhao M; Flynt FL; Hong M; Chen H; Gilbert CA; Briley NT; Bolick SC; Wright KL; Piskurich JF
Mol Immunol; 2007 Apr; 44(11):2923-32. PubMed ID: 17300840
[TBL] [Abstract][Full Text] [Related]
46. Pathologic conditions of hard tissue: role of osteoclasts in osteolytic lesion.
Kitazawa R; Haraguchi R; Fukushima M; Kitazawa S
Histochem Cell Biol; 2018 Apr; 149(4):405-415. PubMed ID: 29356963
[TBL] [Abstract][Full Text] [Related]
47. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
48. Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.
Yang Y; Ren Y; Ramani VC; Nan L; Suva LJ; Sanderson RD
Cancer Res; 2010 Nov; 70(21):8329-38. PubMed ID: 20978204
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of osteoclastogenesis by RNA interference targeting RANK.
Ma R; Xu J; Dong B; Kauther MD; Jäger M; Wedemeyer C
BMC Musculoskelet Disord; 2012 Aug; 13():154. PubMed ID: 22913338
[TBL] [Abstract][Full Text] [Related]
50. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
[TBL] [Abstract][Full Text] [Related]
51. Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.
Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
Curr Drug Targets; 2005 Sep; 6(6):701-11. PubMed ID: 16178802
[TBL] [Abstract][Full Text] [Related]
52. Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Leuk Lymphoma; 2014 Apr; 55(4):911-9. PubMed ID: 23915193
[TBL] [Abstract][Full Text] [Related]
53. An Evidence-Based Approach to Myeloma Bone Disease.
Bingham N; Reale A; Spencer A
Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
[TBL] [Abstract][Full Text] [Related]
54. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades.
Song F; Wei C; Zhou L; Qin A; Yang M; Tickner J; Huang Y; Zhao J; Xu J
J Cell Physiol; 2018 Feb; 233(2):1723-1735. PubMed ID: 28681916
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading.
Plotkin LI; Gortazar AR; Davis HM; Condon KW; Gabilondo H; Maycas M; Allen MR; Bellido T
J Biol Chem; 2015 Jul; 290(31):18934-42. PubMed ID: 26085098
[TBL] [Abstract][Full Text] [Related]
56. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
57. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.
Hjertner O; Torgersen ML; Seidel C; Hjorth-Hansen H; Waage A; Børset M; Sundan A
Blood; 1999 Dec; 94(11):3883-8. PubMed ID: 10572104
[TBL] [Abstract][Full Text] [Related]
58. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
59. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
60. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
